Enanta Pharmaceuticals Inc expected to post a loss of $1.98 a share - Earnings Preview

Enanta Pharmaceuticals

05/05/2023 23:07

* Enanta Pharmaceuticals Inc  ENTA.OQ   ENTA.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 8. 
    * The Watertown Massachusetts-based  company is expected to
report
 a 2.5% increase in revenue to $19.183 million from $18.72
million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Enanta
Pharmaceuticals
Inc is for a loss of $1.98 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Enanta
Pharmaceuticals Inc is $68​, above​ its last closing price
of $36.02. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -1.59       -1.59      -1.39     Beat    12.9
 Sep. 30 2022  -1.40       -1.35      -1.27     Beat    6.1
 Jun. 30 2022  -1.46       -1.39      -1.53     Missed  -10.4​
 Mar. 31 2022  -1.36       -1.43      -1.63     Missed  -14.3
 ​​Dec.        -1.07       -1.08      -1.48     Missed  -36.9
 31 2021                                                
 Sep. 30 2021  -1.17       -1.22      -1.22     Met     0.2​
 Jun. 30 2021  -1.32       -1.28      -1.19     Beat    6.9
 Mar. 31 2021  -1.04       -0.98      -1.09     Missed  -11
 This summary was machine generated May 5 at 22:06 GMT.  All
figures in US dollars  unless otherwise stated